Company Filing History:
Years Active: 2016-2018
Title: Innovations of David Dain in Pharmaceutical Chemistry
Introduction
David Dain is a notable inventor based in Baltimore, MD (US), recognized for his contributions to pharmaceutical chemistry. He has been instrumental in developing methods for producing viloxazine salts and novel polymorphs, which have significant implications in the field of medicine. With a total of 4 patents to his name, Dain continues to push the boundaries of innovation in drug formulation.
Latest Patents
Dain's latest patents focus on the methods for producing viloxazine salts and novel polymorphs thereof. These patents provide comprehensive methods for the manufacture of viloxazine and its various salts, as well as viloxazine-related compounds. The methods ensure a substantially pure active pharmaceutical ingredient (API) of viloxazine HCl while avoiding undesirable impurities. Furthermore, the patents detail processes for separating, identifying, and characterizing novel polymorphs of viloxazine. They also encompass methods for the synthesis and identification of novel intermediates of viloxazine, along with important metabolites and precursors of metabolites.
Career Highlights
David Dain is currently employed at Supernus Pharmaceuticals, Inc., where he applies his expertise in pharmaceutical development. His work has significantly contributed to the advancement of drug formulations, particularly in the area of viloxazine. Dain's innovative approaches have positioned him as a key figure in the pharmaceutical industry.
Collaborations
Dain collaborates with talented professionals in his field, including Likan Liang and Padmanabh P Bhatt. These collaborations enhance the research and development efforts at Supernus Pharmaceuticals, Inc., fostering an environment of innovation and discovery.
Conclusion
David Dain's work in pharmaceutical chemistry exemplifies the impact of innovation on drug development. His patents and collaborations continue to shape the future of medicine, making significant strides in the production of effective pharmaceutical compounds.